Genitourinary cancer predisposition syndromes

Hematology/Oncology Clinics of North America

Volumn 24, Issue 5, 2010, Pages 861-883

  Gallagher, David J ^a   Feifer, Andrew ^a   Coleman, Jonathan A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Genetic; Genitourinary; Predisposition

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; BRCA1 PROTEIN; BRCA2 PROTEIN; GLUTATHIONE TRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

BIRT HOGG DUBE SYNDROME; BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC VARIABILITY; GERM CELL TUMOR; HEREDITARY LEIOMYOMATOSIS RENAL CELL CARCINOMA; HEREDITARY PAPILLARY RENAL CANCER; HEREDITY; HUMAN; KIDNEY CANCER; NEPHRON SPARING SURGERY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEX CORD TUMOR; TESTIS CANCER; TRANSITIONAL CELL CARCINOMA; TUBEROUS SCLEROSIS; UROGENITAL TRACT CANCER; UROGENITAL TRACT TUMOR; VON HIPPEL LINDAU DISEASE;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASTIC SYNDROMES, HEREDITARY; PROSTATIC NEOPLASMS; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 77956314658     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.06.002     Document Type: Review

References (209)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Goldgar D.E., Easton D.F., Cannon-Albright L.A., et al. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994, 86:1600-1608.
3. Mackinnon A.C., Yan B.C., Joseph L.J., et al. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med 2009, 133:1033-1040.
4. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85.
5. Schaid D.J. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004, 13(1):R103-R121.
6. Gronberg H., Damber L., Damber J.E. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994, 152:1484-1487. [discussion: 1487-9].
7. Page W.F., Braun M.M., Partin A.W., et al. Heredity and prostate cancer: a study of World War II veteran twins. Prostate 1997, 33:240-245.
8. Smith J.R., Freije D., Carpten J.D., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996, 274:1371-1374.
9. Gronberg H., Xu J., Smith J.R., et al. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res 1997, 57:4707-4709.
10. Carpten J., Nupponen N., Isaacs S., et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002, 30:181-184.
11. Cooney K.A., McCarthy J.D., Lange E., et al. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997, 89:955-959.
12. Hsieh C.L., Oakley-Girvan I., Gallagher R.P., et al. Re: prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst 1997, 89:1893-1894.
13. McIndoe R.A., Stanford J.L., Gibbs M., et al. Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet 1997, 61:347-353.
14. Eeles R.A., Durocher F., Edwards S., et al. Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet 1998, 62:653-658.
15. Bergthorsson J.T., Johannesdottir G., Arason A., et al. Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer. Hum Genet 2000, 107:372-375.
16. Cancel-Tassin G., Latil A., Valeri A., et al. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. Eur J Hum Genet 2001, 9:135-142.
17. Suarez B.K., Lin J., Witte J.S., et al. Replication linkage study for prostate cancer susceptibility genes. Prostate 2000, 45:106-114.
18. Berry R., Schaid D.J., Smith J.R., et al. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet 2000, 66:539-546.
19. Farnham J.M., Camp N.J., Swensen J., et al. Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees. Hum Genet 2005, 116:179-185.
20. Xu J., Meyers D., Freije D., et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998, 20:175-179.
21. Xu J. Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet 2000, 66:945-957.
22. Berthon P., Valeri A., Cohen-Akenine A., et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998, 62:1416-1424.
23. Gibbs M., Chakrabarti L., Stanford J.L., et al. Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. Am J Hum Genet 1999, 64:1087-1095.
24. Gibbs M., Stanford J.L., McIndoe R.A., et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999, 64:776-787.
25. Whittemore A.S., Lin I.G., Oakley-Girvan I., et al. No evidence of linkage for chromosome 1q42.2-43 in prostate cancer. Am J Hum Genet 1999, 65:254-256.
26. Gronberg H., Wiklund F., Damber J.E. Age specific risks of familial prostate carcinoma: a basis for screening recommendations in high risk populations. Cancer 1999, 86:477-483.
27. Zeegers M.P., Jellema A., Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003, 97:1894-1903.
28. Haas G.P., Sakr W.A. Epidemiology of prostate cancer. CA Cancer J Clin 1997, 47:273-287.
29. Valeri A., Briollais L., Azzouzi R., et al. Segregation analysis of prostate cancer in France: evidence for autosomal dominant inheritance and residual brother-brother dependence. Ann Hum Genet 2003, 67:125-137.
30. Schaid D.J., McDonnell S.K., Blute M.L., et al. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998, 62:1425-1438.
31. Verhage B.A., Baffoe-Bonnie A.B., Baglietto L., et al. Autosomal dominant inheritance of prostate cancer: a confirmatory study. Urology 2001, 57:97-101.
32. Carter B.S., Beaty T.H., Steinberg G.D., et al. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992, 89:3367-3371.
33. Ostrander E.A., Markianos K., Stanford J.L. Finding prostate cancer susceptibility genes. Annu Rev Genomics Hum Genet 2004, 5:151-175.
34. Langeberg W.J., Isaacs W.B., Stanford J.L. Genetic etiology of hereditary prostate cancer. Front Biosci 2007, 12:4101-4110.
35. Walz J., Gallina A., Perrotte P., et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 2007, 100:1254-1258.
36. Kirchhoff T., Kauff N.D., Mitra N., et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004, 10:2918-2921.
37. Hubert A., Peretz T., Manor O., et al. The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 1999, 65:921-924.
38. Lehrer S., Fodor F., Stock R.G., et al. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 1998, 78:771-773.
39. Nastiuk K.L., Mansukhani M., Terry M.B., et al. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999, 40:172-177.
40. Vazina A., Baniel J., Yaacobi Y., et al. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 2000, 83:463-466.
41. Giusti R.M., Rutter J.L., Duray P.H., et al. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 2003, 40:787-792.
42. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336:1401-1408.
43. Warner E., Foulkes W., Goodwin P., et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999, 91:1241-1247.
44. Agalliu I., Karlins E., Kwon E.M., et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 2007, 97:826-831.
45. Douglas J.A., Levin A.M., Zuhlke K.A., et al. Common variation in the BRCA1 gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007, 16:1510-1516.
46. Willems A.J., Dawson S.J., Samaratunga H., et al. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clin Cancer Res 2008, 14:2953-2961.
47. Thompson D., Easton D.F. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002, 94:1358-1365.
48. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999, 91:1310-1316.
49. Tryggvadóttir L., Vidarsdóttir L., Thorgeirsson T., et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007, 99:929-935.
50. Gallagher D.J., Gaudet M.M., Pal P., et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010, 16(7):2115-2121.
51. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
52. Dong X., Wang L., Taniguchi K., et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003, 72:270-280.
53. Wu X., Dong X., Liu W., et al. Characterization of CHEK2 mutations in prostate cancer. Hum Mutat 2006, 27:742-747.
54. Cybulski C., Wokolorczyk D., Huzarski T., et al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 2006, 43:863-866.
55. Cybulski C., Huzarski T., Gorski B., et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004, 64:2677-2679.
56. Tischkowitz M.D., Yilmaz A., Chen L.Q., et al. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Lett 2008, 270:173-180.
57. Rokman A., Ikonen T., Seppala E.H., et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002, 70:1299-1304.
58. Rennert H., Bercovich D., Hubert A., et al. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002, 71:981-984.
59. Gronberg H., Isaacs S.D., Smith J.R., et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 1997, 278:1251-1255.
60. Goode E.L., Stanford J.L., Chakrabarti L., et al. Linkage analysis of 150 high-risk prostate cancer families at 1q24-25. Genet Epidemiol 2000, 18:251-275.
61. Eeles R.A., Kote-Jarai Z., Giles G.G., et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008, 40:316-321.
62. Thomas G., Jacobs K.B., Yeager M., et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008, 40:310-315.
63. Yeager M., Orr N., Hayes R.B., et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007, 39:645-649.
64. Yeager M., Chatterjee N., Ciampa J., et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet 2009, 41:1055-1057.
65. Eeles R.A., Kote-Jarai Z., Al Olama A.A., et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009, 41:1116-1121.
66. Gudmundsson J., Sulem P., Manolescu A., et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007, 39:631-637.
67. Gudmundsson J., Sulem P., Rafnar T., et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008, 40:281-283.
68. Gudmundsson J., Sulem P., Gudbjartsson D.F., et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009, 41:1122-1126.
69. Amundadottir L.T., Sulem P., Gudmundsson J., et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006, 38:652-658.
70. Freedman M.L., Haiman C.A., Patterson N., et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006, 103:14068-14073.
71. Al Olama A.A., Kote-Jarai Z., Giles G.G., et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009, 41:1058-1060.
72. Sun J., Zheng S.L., Wiklund F., et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008, 40:1153-1155.
73. Sole X., Hernandez P., de Heredia M.L., et al. Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility. BMC Genomics 2008, 9:12.
74. Pomerantz M.M., Ahmadiyeh N., Jia L., et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 2009, 41:882-884.
75. Tuupanen S., Turunen M., Lehtonen R., et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 2009, 41:885-890.
76. Cybulski C., Gorski B., Debniak T., et al. NBS1 is a prostate cancer susceptibility gene. Cancer Res 2004, 64:1215-1219.
77. Beebe-Dimmer J.L., Levin A.M., Ray A.M., et al. Chromosome 8q24 markers: risk of early-onset and familial prostate cancer. Int J Cancer 2008, 122:2876-2879.
78. Jung I., Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 2000, 7:325-334.
79. Kogevinas M., Fernandez F., Garcia-Closas M., et al. Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain. Eur J Cancer 2006, 42:1448-1454.
80. Morris R.D., Audet A.M., Angelillo I.F., et al. Chlorination, chlorination by-products, and cancer: a meta-analysis. Am J Public Health 1992, 82:955-963.
81. Marshall G., Ferreccio C., Yuan Y., et al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 2007, 99:920-928.
82. Cantor K.P., Lynch C.F., Hildesheim M.E., et al. Drinking water source and chlorination byproducts. I. Risk of bladder cancer. Epidemiology 1998, 9:21-28.
83. Lillienfeld A., Levin M. The association of smoking with cancer of the urinary bladder in humans. Arch Intern Med 1956, 98:129-135.
84. Mueller C.M., Caporaso N., Greene M.H. Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol 2008, 26:451-464.
85. Aben K.K., Witjes J.A., Schoenberg M.P., et al. Familial aggregation of urothelial cell carcinoma. Int J Cancer 2002, 98:274-278.
86. Randi G., Pelucchi C., Negri E., et al. Family history of urogenital cancers in patients with bladder, renal cell and prostate cancers. Int J Cancer 2007, 121:2748-2752.
87. Cartwright R.A. Genetic association with bladder cancer. Br Med J 1979, 2:798.
88. Kantor A.F., Hartge P., Hoover R.N., et al. Familial and environmental interactions in bladder cancer risk. Int J Cancer 1985, 35:703-706.
89. Kiemeney L.A., Moret N.C., Witjes J.A., et al. Familial transitional cell carcinoma among the population of Iceland. J Urol 1997, 157:1649-1651.
90. Kramer A.A., Graham S., Burnett W.S., et al. Familial aggregation of bladder cancer stratified by smoking status. Epidemiology 1991, 2:145-148.
91. Kunze E., Chang-Claude J., Frentzel-Beyme R. Life style and occupational risk factors for bladder cancer in Germany. A case-control study. Cancer 1992, 69:1776-1790.
92. Lin J., Spitz M.R., Dinney C.P., et al. Bladder cancer risk as modified by family history and smoking. Cancer 2006, 107:705-711.
93. Lynch H.T., Kimberling W.J., Lynch J.F., et al. Familial bladder cancer in an oncology clinic. Cancer Genet Cytogenet 1987, 27:161-165.
94. Piper J.M., Matanoski G.M., Tonascia J. Bladder cancer in young women. Am J Epidemiol 1986, 123:1033-1042.
95. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261-268.
96. Sijmons R.H., Kiemeney L.A., Witjes J.A., et al. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options. J Urol 1998, 160:466-470.
97. Burt R.W., Barthel J.S., Dunn K.B., et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2010, 8:8-61.
98. Draper G.J., Sanders B.M., Kingston J.E. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986, 53:661-671.
99. Schlienger P., Campana F., Vilcoq J.R., et al. Nonocular second primary tumors after retinoblastoma: retrospective study of 111 patients treated by electron beam radiotherapy with or without TEM. Am J Clin Oncol 2004, 27:411-419.
100. Fletcher O., Easton D., Anderson K., et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004, 96:357-363.
101. Wu X.R. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005, 5:713-725.
102. Hennekam R.C. Costello syndrome: an overview. Am J Med Genet C Semin Med Genet 2003, 117C:42-48.
103. Aoki Y., Niihori T., Kawame H., et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005, 37:1038-1040.
104. Silverman D.T., Devesa S.S., Moore L.E., et al. Bladder cancer 2006, Oxford University Press, New York. 3rd edition.
105. Garte S., Gaspari L., Alexandrie A.K., et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001, 10:1239-1248.
106. Hein D.W., Doll M.A., Fretland A.J., et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000, 9:29-42.
107. Garcia-Closas M., Malats N., Silverman D., et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005, 366:649-659.
108. Kiemeney L.A., Thorlacius S., Sulem P., et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008, 40:1307-1312.
109. Witte J.S. Prostate cancer genomics: towards a new understanding. Nat Rev Genet 2009, 10:77-82.
110. Wu X., Ye Y., Kiemeney L.A., et al. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 2009, 41:991-995.
111. Zbar B., Glenn G., Merino M., et al. Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development. J Urol 2007, 177:461-465. [discussion: 465].
112. Duan D.R., Humphrey J.S., Chen D.Y., et al. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A 1995, 92:6459-6463.
113. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
114. Molino D., Sepe J., Anastasio P., et al. The history of von Hippel-Lindau disease. J Nephrol 2006, 19(Suppl 10):S119-S123.
115. Davison C., Brock S., Dyke C.G. Retinal and central nervous hemangioblastomatosis with visceral changes (von Hippel-Lindau's disease). Bull Neurol Instit NY 1936, 5:72-93.
116. Seizinger B.R., Rouleau G.A., Ozelius L.J., et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988, 332:268-269.
117. Pfaffenroth E.C., Linehan W.M. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther 2008, 8:779-790.
118. Zbar B., Kishida T., Chen F., et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996, 8:348-357.
119. Lonser R.R., Glenn G.M., Walther M., et al. von Hippel-Lindau disease. Lancet 2003, 361:2059-2067.
120. Wong W.T., Agron E., Coleman H.R., et al. Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Arch Ophthalmol 2007, 125:239-245.
121. Schmidt L., Duh F.M., Chen F., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68-73.
122. Lindor N.M., Dechet C.B., Greene M.H., et al. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test 2001, 5:101-106.
123. Schmidt L.S., Nickerson M.L., Angeloni D., et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 2004, 172:1256-1261.
124. Miyata Y., Kanetake H., Kanda S. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma. Clin Cancer Res 2006, 12:4876-4881.
125. Dharmawardana P.G., Giubellino A., Bottaro D.P. Hereditary papillary renal carcinoma type I. Curr Mol Med 2004, 4:855-868.
126. Fischer J., Palmedo G., von Knobloch R., et al. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 1998, 17:733-739.
127. Palmedo G., Fischer J., Kovacs G. Duplications of DNA sequences between loci D20S478 and D20S206 at 20q11.2 and between loci D20S902 and D20S480 at 20q13.2 mark new tumor genes in papillary renal cell carcinoma. Lab Invest 1999, 79:311-316.
128. Zbar B., Glenn G., Lubensky I., et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 1995, 153:907-912.
129. Schmidt L., Junker K., Weirich G., et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 1998, 58:1719-1722.
130. Ornstein D.K., Lubensky I.A., Venzon D., et al. Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol 2000, 163:431-433.
131. Bellon S.F., Kaplan-Lefko P., Yang Y., et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008, 283:2675-2683.
132. Menko F.H., van Steensel M.A., Giraud S., et al. Birt-Hogg-Dube syndrome: diagnosis and management. Lancet Oncol 2009, 10:1199-1206.
133. Linehan W.M., Pinto P.A., Bratslavsky G., et al. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 2009, 115:2252-2261.
134. Zbar B., Alvord W.G., Glenn G., et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 2002, 11:393-400.
135. Wei M.H., Toure O., Glenn G.M., et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 2006, 43:18-27.
136. Toro J.R., Wei M.H., Glenn G.M., et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet 2008, 45:321-331.
137. Murakami T., Sano F., Huang Y., et al. Identification and characterization of Birt-Hogg-Dube associated renal carcinoma. J Pathol 2007, 211:524-531.
138. Durrani O.H., Ng L., Bihrle W. Chromophobe renal cell carcinoma in a patient with the Birt-Hogg-Dube syndrome. J Urol 2002, 168:1484-1485.
139. Nagashima Y., Mitsuya T., Shioi K.I., et al. Renal oncocytosis. Pathol Int 2005, 55:210-215.
140. Imada K., Dainichi T., Yokomizo A., et al. Birt-Hogg-Dube syndrome with clear-cell and oncocytic renal tumour and trichoblastoma associated with a novel FLCN mutation. Br J Dermatol 2009, 160:1350-1353.
141. Mai K.T., Dhamanaskar P., Belanger E., et al. Hybrid chromophobe renal cell neoplasm. Pathol Res Pract 2005, 201:385-389.
142. Adley B.P., Schafernak K.T., Yeldandi A.V., et al. Cytologic and histologic findings in multiple renal hybrid oncocytic tumors in a patient with Birt-Hogg-Dube syndrome: a case report. Acta Cytol 2006, 50:584-588.
143. Pavlovich C.P., Walther M.M., Eyler R.A., et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 2002, 26:1542-1552.
144. Adley B.P., Smith N.D., Nayar R., et al. Birt-Hogg-Dube syndrome: clinicopathologic findings and genetic alterations. Arch Pathol Lab Med 2006, 130:1865-1870.
145. Khoo S.K., Bradley M., Wong F.K., et al. Birt-Hogg-Dube syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. Oncogene 2001, 20:5239-5242.
146. Hudon V., Sabourin S., Dydensborg A.B., et al. Renal tumor suppressor function of the Birt-Hogg-Dube syndrome gene product folliculin. J Med Genet 2009, 47(3):182-189.
147. Schmidt L.S., Warren M.B., Nickerson M.L., et al. Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 2001, 69:876-882.
148. Warren M.B., Torres-Cabala C.A., Turner M.L., et al. Expression of Birt-Hogg-Dube gene mRNA in normal and neoplastic human tissues. Mod Pathol 2004, 17:998-1011.
149. Nickerson M.L., Warren M.B., Toro J.R., et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002, 2:157-164.
150. Schmidt L.S., Nickerson M.L., Warren M.B., et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 2005, 76:1023-1033.
151. Baba M., Hong S.B., Sharma N., et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A 2006, 103:15552-15557.
152. Kiuru M., Launonen V. Hereditary leiomyomatosis and renal cell cancer (HLRCC). Curr Mol Med 2004, 4:869-875.
153. Sudarshan S., Linehan W.M., Neckers L. HIF and fumarate hydratase in renal cancer. Br J Cancer 2007, 96:403-407.
154. Merino M.J., Torres-Cabala C., Pinto P., et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007, 31:1578-1585.
155. Stewart L., Glenn G.M., Stratton P., et al. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. Arch Dermatol 2008, 144:1584-1592.
156. Toro J.R., Nickerson M.L., Wei M.H., et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003, 73:95-106.
157. Lehtonen R., Kiuru M., Vanharanta S., et al. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol 2004, 164:17-22.
158. Alam N.A., Bevan S., Churchman M., et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet 2001, 68:1264-1269.
159. Alam N.A., Olpin S., Rowan A., et al. Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer. J Mol Diagn 2005, 7:437-443.
160. Pollard P.J., Briere J.J., Alam N.A., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005, 14:2231-2239.
161. Heinritz W., Paasch U., Sticherling M., et al. Evidence for a founder effect of the germline fumarate hydratase gene mutation R58P causing hereditary leiomyomatosis and renal cell cancer (HLRCC). Ann Hum Genet 2008, 72:35-40.
162. Tomlinson I.P., Alam N.A., Rowan A.J., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30:406-410.
163. Alam N.A., Rowan A.J., Wortham N.C., et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003, 12:1241-1252.
164. Wortham N.C., Alam N.A., Barclay E., et al. Aberrant expression of apoptosis proteins and ultrastructural aberrations in uterine leiomyomas from patients with hereditary leiomyomatosis and renal cell carcinoma. Fertil Steril 2006, 86:961-971.
165. Pollard P., Wortham N., Barclay E., et al. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 2005, 205:41-49.
166. Lehtonen H.J., Blanco I., Piulats J.M., et al. Conventional renal cancer in a patient with fumarate hydratase mutation. Hum Pathol 2007, 38:793-796.
167. Sudarshan S., Linehan W.M. Genetic basis of cancer of the kidney. Semin Oncol 2006, 33:544-551.
168. Hwang J.J., Walther M.M., Pautler S.E., et al. Radio frequency ablation of small renal tumors: intermediate results. J Urol 2004, 171:1814-1818.
169. Huang W.C., Levey A.S., Serio A.M., et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006, 7:735-740.
170. Coleman J., Singh A., Pinto P., et al. Radiofrequency-assisted laparoscopic partial nephrectomy: clinical and histologic results. J Endourol 2007, 21:600-605.
171. Hwang J.J., Uchio E.M., Pavlovich C.P., et al. Surgical management of multi-organ visceral tumors in patients with von Hippel-Lindau disease: a single stage approach. J Urol 2003, 169:895-898.
172. Grubb RL, Corbin NS, Choyke P, et al. Analysis of 3-cm tumor size threshold for intervention in patients with Birt-Hogg-Dubé and hereditary papillary renal cancer [abstract 980]. American Urological Association National Conference; 2005.
173. Bratslavsky G., Liu J.J., Johnson A.D., et al. Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol 2008, 179:67-70.
174. Herring J.C., Enquist E.G., Chernoff A., et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 2001, 165:777-781.
175. Pinto P.A. Renal carcinoma: minimally invasive surgery of the small renal mass. Urol Oncol 2009, 27:335-336.
176. Hsieh T.C., Jarrett T.W., Pinto P.A. Current status of nephron-sparing robotic partial nephrectomy. Curr Opin Urol 2010, 20:65-69.
177. Russo P. Partial nephrectomy achieves local tumor control and prevents chronic kidney disease. Expert Rev Anticancer Ther 2006, 6:1745-1751.
178. Webster A.R., Maher E.R., Moore A.T. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol 1999, 117:371-378.
179. Butman J.A., Linehan W.M., Lonser R.R. Neurologic manifestations of von Hippel-Lindau disease. JAMA 2008, 300:1334-1342.
180. Ammerman J.M., Lonser R.R., Dambrosia J., et al. Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg 2006, 105:248-255.
181. Baghai M., Thompson G.B., Young W.F., et al. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery. Arch Surg 2002, 137:682-688. [discussion: 688-9].
182. Diner E.K., Franks M.E., Behari A., et al. Partial adrenalectomy: the National Cancer Institute experience. Urology 2005, 66:19-23.
183. Launonen V., Vierimaa O., Kiuru M., et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001, 98:3387-3392.
184. Refae M.A., Wong N., Patenaude F., et al. Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma. Nat Clin Pract Oncol 2007, 4:256-261.
185. Grubb R.L., Franks M.E., Toro J., et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007, 177:2074-2079. [discussion: 2079-80].
186. Alrashdi I., Levine S., Paterson J., et al. Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient. Fam Cancer 2009, 9(2):239-243.
187. Sudarshan S., Pinto P.A., Neckers L., et al. Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer-a distinct form of hereditary kidney cancer. Nat Clin Pract Urol 2007, 4:104-110.
188. Rosner I., Bratslavsky G., Pinto P.A., et al. The clinical implications of the genetics of renal cell carcinoma. Urol Oncol 2009, 27:131-136.
189. Houldsworth J., Korkola J.E., Bosl G.J., et al. Biology and genetics of adult male germ cell tumors. J Clin Oncol 2006, 24:5512-5518.
190. Sharpe R.M., Skakkebaek N.E. Testicular dysgenesis syndrome: mechanistic insights and potential new downstream effects. Fertil Steril 2008, 89:e33-e38.
191. Nathanson K.L., Kanetsky P.A., Hawes R., et al. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet 2005, 77:1034-1043.
192. Heimdal K., Olsson H., Tretli S., et al. Familial testicular cancer in Norway and southern Sweden. Br J Cancer 1996, 73:964-969.
193. Hemminki K., Li X. Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br J Cancer 2004, 90:1765-1770.
194. Westergaard T., Olsen J.H., Frisch M., et al. Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population-based study. Int J Cancer 1996, 66:627-631.
195. Giambartolomei C., Mueller C.M., Greene M.H., et al. A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome. Cancer Epidemiol 2009, 33:31-36.
196. Crockford G.P., Linger R., Hockley S., et al. Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet 2006, 15:443-451.
197. Skakkebaek N.E. Possible carcinoma-in-situ of the testis. Lancet 1972, 2:516-517.
198. Kanetsky P.A., Mitra N., Vardhanabhuti S., et al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 2009, 41:811-815.
199. Rapley E.A., Turnbull C., Al Olama A.A., et al. A genome-wide association study of testicular germ cell tumor. Nat Genet 2009, 41:807-810.
200. Rajpert-De Meyts E., Skakkebaek N.E. Expression of the c-kit protein product in carcinoma-in-situ and invasive testicular germ cell tumours. Int J Androl 1994, 17:85-92.
201. Dieckmann K.P., Loy V. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol 1996, 14:3126-3132.
202. Sasaki A., Taketomi T., Kato R., et al. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol 2003, 5:427-432.
203. Frolov A., Chahwan S., Ochs M., et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2003, 2:699-709.
204. Washecka R., Dresner M.I., Honda S.A. Testicular tumors in Carney's complex. J Urol 2002, 167:1299-1302.
205. Proppe K.H., Scully R.E. Large-cell calcifying Sertoli cell tumor of the testis. Am J Clin Pathol 1980, 74:607-619.
206. Gourlay W.A., Johnson H.W., Pantzar J.T., et al. Gonadal tumors in disorders of sexual differentiation. Urology 1994, 43:537-540.
207. Jeghers H., Mc K.V., Katz K.H. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med 1949, 241:1031-1036.
208. Ulbright T.M., Amin M.B., Young R.H. Intratubular large cell hyalinizing Sertoli cell neoplasia of the testis: a report of 8 cases of a distinctive lesion of the Peutz-Jeghers syndrome. Am J Surg Pathol 2007, 31:827-835.
209. Boikos S.A., Stratakis C.A. Carney complex: the first 20 years. Curr Opin Oncol 2007, 19:24-29.